{
    "clinical_study": {
        "@rank": "114209", 
        "acronym": "ALPPS", 
        "arm_group": [
            {
                "arm_group_label": "ALPPS", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant"
            }, 
            {
                "arm_group_label": "PVO", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient undergo portal vein embolization or ligation"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial compares how well associating liver partition with portal\n      vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in\n      treating patients with liver cancer. Both treatments are types of 2-stage hepatectomies for\n      removing liver cancer. ALPPS may be more effective than PVO in patients whose disease would\n      traditionally be considered inoperable.\n\n        -  Trial with surgical intervention"
        }, 
        "brief_title": "ALLPS VERSUS PVO Randomized Controlled Trial", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Tumors Not Resectable in One Surgical Procedure", 
        "condition_browse": {
            "mesh_term": "Liver Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria: \u2022Patient may have primary or secondary hepatic malignancies with a\n        FLR/TLV < 30% or a FLR/BW ratio of < 0.5 for patients with normal liver function (defined\n        as normal transaminases, normal bilirubin, normal factor V, and normal PT/INR). In case of\n        injury due to chemotherapy, known high grade steatosis, or cholestasis > 50 mmol/L,\n        patient may be enrolled into the trial if FLR/TLV is < 40% or FLR/BW ratio < 0.8.\n\n          -  Patient must have extensive liver tumors that would require portal vein embolization\n             or a two-stage hepatectomy and portal vein embolization or ligation by the judgment\n             of surgeons in the tumor board.\n\n          -  Patient may have extrahepatic disease as long as it may be addressed after liver\n             surgery and there is a tumor board decision to proceed with liver resection (mostly\n             applicable to CRC metastases).\n\n          -  Patient may have received previous chemotherapy.\n\n          -  In cases of cholestasis, preoperative drainage procedures (PTC or ERCP) are left up\n             to judgement of physicians.\n\n          -  Patient must be = 18 years of age. The patient population over 65 years old needs to\n             be carefully included based on comorbidities.\n\n          -  Patient may have undergone previous liver resection.\n\n          -  Patient's location must be such that proper staging and follow-up may be performed.\n\n          -  Patient's case must be presented at the Multidisciplinary Meeting attended by\n             hepatobiliary surgeons, oncologists, hepatologists, and radiologists, or must be\n             approved directly by Dr. Strasberg or Dr. Chapman.\n\n        Exclusion criteria: \u2022Patient must not have any significant concomitant diseases rendering\n        him/her unsuitable for major liver surgery by the judgment of the physicians involved,\n        especially if the patient is > 65 years old.\n\n          -  Patient must not have enrolled into a clinical trial within 4 weeks of study entry.\n\n          -  Patient must not have peritoneal carcinomatosis or other extensive extrahepatic\n             disease.\n\n          -  Patient must not have advanced stages of carcinoma of the gallbladder (T3/T4)\n\n          -  Patient must not have issues such as drug and/or alcohol abuse.\n\n          -  Patient must not need major extrahepatic surgery (e.g. pancreas resection, gastric\n             resection, rectal surgery) within 3 months of study entry.\n\n          -  Patient must not be a candidate for liver transplantation in case of HCC.\n\n          -  Patient must not be pregnant or breastfeeding. If a female of childbearing potential,\n             patient must have a negative pregnancy test within 14 days of enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775267", 
            "org_study_id": "USZ-ZH-VIS-ALPPS"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALPPS", 
                "intervention_name": "Associating liver partition and portal vein ligation for staged hepatectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "PVO", 
                "intervention_name": "Portal vein embolization or ligation", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2013", 
        "location": [
            {
                "contact": {
                    "email": "strasberg@wudosis.wustl.edu", 
                    "last_name": "Steven Strasberg, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University"
                }, 
                "investigator": {
                    "last_name": "Steven Strasberg, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "victoria.ardiles@hospitalitaliano.org.ar", 
                    "last_name": "Victoria Ardiles, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }, 
                    "name": "Italian Hospital, Department of Surgery, Division of HPB surgery and Liver Transplatn Unit"
                }, 
                "investigator": {
                    "last_name": "Eduardo De Santibanes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "erik.schadde@usz.ch", 
                    "last_name": "Erik Schadde, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "state": "ZH", 
                        "zip": "8091"
                    }, 
                    "name": "University Hospital Zurich, Division of Visceral and Transplant Surgery"
                }, 
                "investigator": {
                    "last_name": "Pierre-Alain Clavien, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial", 
        "overall_contact": {
            "email": "erik.schadde@usz.ch", 
            "last_name": "Erik Schadde, MD", 
            "phone": "+41 (0)44 255 11 11"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Division of Visceral and Transplant Surgery", 
            "last_name": "Erik Schadde, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Swissmedic", 
                "United States: Food and Drug Administration", 
                "Argentina: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ]", 
            "safety_issue": "No", 
            "time_frame": "2012 to 2015"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775267"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "rate of hypertrophy over time", 
                "safety_issue": "No", 
                "time_frame": "2012 to 2015"
            }, 
            {
                "measure": "Complications of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "2012-2015"
            }, 
            {
                "description": "Progression free survival", 
                "measure": "Progression of disease", 
                "safety_issue": "No", 
                "time_frame": "2012-2015"
            }, 
            {
                "measure": "Postoperative liver and renal function", 
                "safety_issue": "Yes", 
                "time_frame": "2012 to 2015"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}